About
Professor Susana Banerjee is a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at The Royal Marsden NHS Foundation Trust, and Professor in Women’s Cancers at The Institute of Cancer Research. She is also the current President of the Royal Society of Medicine Oncology Section. Internationally recognised for her leadership in gynaecological oncology, she specialises in ovarian cancer and the systemic treatment of endometrial and cervical cancers.
Professor Banerjee graduated with First Class Honours in Physiology from St John’s College, University of Cambridge, where she also served as President of the Cambridge Medical Society. She completed her medical degree at The Royal Free and University College London Medical School, finishing as a University of London Gold Medal finalist. She went on to earn a PhD from The Institute of Cancer Research in 2009, receiving the prestigious San Antonio Breast Cancer Symposium Novartis Oncology Basic Science Award for her research. Her achievements have been recognised with multiple awards, including the Association of Cancer Physicians McElwain Prize, the Sir Antony Driver Prize, the Pfizer BOA Young Investigator Award (highly commended), and the Fellow of ESMO (FESMO) Award in 2023.
Throughout her career, Professor Banerjee has played major roles in international oncology leadership. She has served on specialist committees for the European Organization for Research and Treatment of Cancer, the European Society of Gynaecological Oncology, and the International Gynecologic Cancer Society. She was elected to the Executive Board of the European Society for Medical Oncology as Director of Membership from 2020 to 2022, and has held key scientific leadership positions at major global conferences, including ESMO Congress, ESMO Asia, and the ESMO Gynaecological Cancers Congress. She currently co-chairs the GCIG Rare Cancers Committee and serves as Theme Lead for Cancer Treatment Effects at the NIHR Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research.
A highly respected clinical scientist, Professor Banerjee has authored more than 185 peer-reviewed publications in leading journals such as The New England Journal of Medicine, The Lancet, Lancet Oncology, Journal of Clinical Oncology and Annals of Oncology. Her research focuses on personalised cancer treatment, targeted therapies including PARP inhibitors, and rare gynaecological cancers. She has served as Global or UK Chief Investigator for over 30 national and international clinical trials.
Professor Banerjee graduated with First Class Honours in Physiology from St John’s College, University of Cambridge, where she also served as President of the Cambridge Medical Society. She completed her medical degree at The Royal Free and University College London Medical School, finishing as a University of London Gold Medal finalist. She went on to earn a PhD from The Institute of Cancer Research in 2009, receiving the prestigious San Antonio Breast Cancer Symposium Novartis Oncology Basic Science Award for her research. Her achievements have been recognised with multiple awards, including the Association of Cancer Physicians McElwain Prize, the Sir Antony Driver Prize, the Pfizer BOA Young Investigator Award (highly commended), and the Fellow of ESMO (FESMO) Award in 2023.
Throughout her career, Professor Banerjee has played major roles in international oncology leadership. She has served on specialist committees for the European Organization for Research and Treatment of Cancer, the European Society of Gynaecological Oncology, and the International Gynecologic Cancer Society. She was elected to the Executive Board of the European Society for Medical Oncology as Director of Membership from 2020 to 2022, and has held key scientific leadership positions at major global conferences, including ESMO Congress, ESMO Asia, and the ESMO Gynaecological Cancers Congress. She currently co-chairs the GCIG Rare Cancers Committee and serves as Theme Lead for Cancer Treatment Effects at the NIHR Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research.
A highly respected clinical scientist, Professor Banerjee has authored more than 185 peer-reviewed publications in leading journals such as The New England Journal of Medicine, The Lancet, Lancet Oncology, Journal of Clinical Oncology and Annals of Oncology. Her research focuses on personalised cancer treatment, targeted therapies including PARP inhibitors, and rare gynaecological cancers. She has served as Global or UK Chief Investigator for over 30 national and international clinical trials.
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
— Professor Susana Banerjee
Education & training
-
2017–2023 MD · Medicine and Surgery
-
2023–2027 Residency · Oncology
Career & appointments
-
2027-09–2028-08 Junior consultant
Licenses & insurance
Medical licenses
GB — Organización Médica Colegial de España (OMC)
Board certifications
European Board of Oncology
Malpractice insurance:
AmTrust Europe · 1,000,000 EUR coverage · No claims on file
Procedures performed
| Procedure | Code | Lifetime count |
|---|---|---|
| GP consultation | 99213 | 731 |
| Annual physical exam | 99395 | 789 |
| Vaccination administration | 90471 | 501 |
| Minor procedure (skin) | 17110 | 1,258 |
Services & pricing
| Service | Duration | Modality | Price |
|---|---|---|---|
| New patient consultation (60m) | 60 min | in_clinic|telemed | 180.00 EUR |
| Follow-up consultation (30m) | 30 min | in_clinic|telemed|phone | 90.00 EUR |
| Vaccination administration | 90 min | in_clinic | 720.00 EUR |
| Minor procedure (skin) | 60 min | in_clinic | 630.00 EUR |
Office, team & in practice
Videos
Research & publications
h-index: 20 · i10: 5
-
Validation of clinical scoring in Oncology
DOI: 10.6391/euroclin.2026.0 · PMID: 35588298 · cited by 131
-
Long-term follow-up of Oncology across GB
DOI: 10.2785/euroclin.2025.1 · PMID: 36302018 · cited by 41
-
Validation of clinical scoring in Oncology
DOI: 10.6621/euroclin.2024.2 · PMID: 30906490 · cited by 151
-
Long-term follow-up of Oncology across GB
DOI: 10.3758/euroclin.2023.3 · PMID: 33369808 · cited by 29
Invited talks
- Practical updates in Oncology European Annual Congress (Oncology) · Vienna · 2024 · invited
- Single-centre experience in Oncology National Society Meeting · London · 2023 · oral abstract
Awards & memberships
Awards
- 🏆 Top-rated Oncology — London · EuroClinics Patient Choice · 2025 · regional
- 🏆 Excellence in Patient Care · National Society · 2024 · national
- 🏆 Young Investigator Award · European Society · 2023 · international
Society memberships
- WONCA Europe — Family Doctors — Member · Since 2028
- national college of family doctors — Member · Since 2028
- European Union of Medical Specialists (UEMS) — Member · Since 2028
Articles by this doctor
- Patient education Patient guide to Oncology
- Awareness When should you see a oncology?
For international patients
- Coordinator
- Patient liaison · dr.susana.banerjee@euroclinics.example
- Accepted international insurance
- Allianz Worldwide · AXA Global · BUPA Global · Cigna Global
Location
1 tagPatient reviews
2 verified reviews5.00
★★★★★
2 reviews
- Bedside Manner
- 5.0
- Knowledge
- 5.0
- Wait Time
- 4.8
- Staff Friendliness
- 5.0
- Ease Of Appointment
- 4.9
- Value For Money
- 4.9
- Would Recommend Pct
- 99.0
Share your experience — help other patients find the right doctor. Write a review →
Recent reviews
-
★★★★★ ✓ Verified Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.
-
★★★★★ ✓ Verified Took time to listen and reviewed all my previous results. I would absolutely recommend.
-
★★★★☆ ✓ Verified Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.
